Education
About Us
Working with TipRanks
Follow Us
Imugene Ltd (AU:IMU)
:IMU
IMU Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$2.75
Previous CloseN/A
Volume11.90M
Average Volume (3M)602.77K
Market Cap
AU$82.40M
Enterprise ValueAU$63.39M
Total Cash (Recent Filing)AU$33.74M
Total Debt (Recent Filing)AU$15.76M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 27, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding219,728,300
10 Day Avg. Volume655,773
30 Day Avg. Volume602,774
Financial Highlights & Ratios
PEG Ratio-1.47
Price to Book (P/B)49.76
Price to Sales (P/S)0.00
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
Imugene News
PremiumCompany Announcements
Imugene Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Imugene to Host Webinar on Azer-cel Phase 1b Trial Data
PremiumCompany Announcements
Imugene Limited Announces Share and Options Offer to Raise $37.5 Million
PremiumCompany Announcements
Imugene Limited Announces Capital Raising for Cancer Treatment Innovations
PremiumCompany Announcements
Imugene Secures $22.5M in Funding, Launches $15M Share Purchase PlanPremiumCompany Announcements
Imugene Limited Initiates Trading Halt for Capital Raising AnnouncementOptions Prices
Currently, No data available
---
Ownership Overview
7.27% Insiders
2.54%
Mutual Funds
<0.01% Other Institutional Investors
87.34% Public Companies and
Individual Investors
IMU FAQ
What was Imugene Ltd’s price range in the past 12 months?
Imugene Ltd lowest share price was AU$0.34 and its highest was AU$2.75 in the past 12 months.
What is Imugene Ltd’s market cap?
Imugene Ltd’s market cap is AU$82.40M.
When is Imugene Ltd’s upcoming earnings report date?
Imugene Ltd’s upcoming earnings report date is Aug 27, 2025 which is in 38 days.
How were Imugene Ltd’s earnings last quarter?
Imugene Ltd released its earnings results on Feb 27, 2025. The company reported -AU$0.222 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.118.
Is Imugene Ltd overvalued?
According to Wall Street analysts Imugene Ltd’s price is currently Overvalued.
Does Imugene Ltd pay dividends?
Imugene Ltd does not currently pay dividends.
What is Imugene Ltd’s EPS estimate?
Imugene Ltd’s EPS estimate is -0.34.
How many shares outstanding does Imugene Ltd have?
Imugene Ltd has 219,728,300 shares outstanding.
What happened to Imugene Ltd’s price movement after its last earnings report?
Imugene Ltd reported an EPS of -AU$0.222 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -2.556%.
Which hedge fund is a major shareholder of Imugene Ltd?
Currently, no hedge funds are holding shares in AU:IMU
Imugene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:IMU Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.88%
12-Months-Change
Fundamentals
Return on Equity
-99.05%
Trailing 12-Months
Asset Growth
-52.38%
Trailing 12-Months
Company Description
Imugene Ltd
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Technical Analysis
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―